Sullivan v. Fellows Testagar & Co.

518 So. 2d 1111, 1987 La. App. LEXIS 10898, 1987 WL 2803
CourtLouisiana Court of Appeal
DecidedDecember 15, 1987
DocketNo. CA-7598
StatusPublished
Cited by1 cases

This text of 518 So. 2d 1111 (Sullivan v. Fellows Testagar & Co.) is published on Counsel Stack Legal Research, covering Louisiana Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Sullivan v. Fellows Testagar & Co., 518 So. 2d 1111, 1987 La. App. LEXIS 10898, 1987 WL 2803 (La. Ct. App. 1987).

Opinion

KLEES, Judge.

Defendant American Cyanamid Company (hereinafter “Cyanamid”) appeals the dismissal of its cross claim against co-defendant Tenneco Resins, Inc. (hereinafter “TRI”). The district court dismissed the claim after maintaining TRI’s exception to the in personam jurisdiction of the court. We affirm.

Appellant and appellee herein are two of several corporations made defendants in this drugs products liability action. Plaintiffs allege that the death of their decedent, Faye Ann Sullivan, was caused by the administration of the drug “Thorotrast.”

Prior to 1953, Thorotrast was manufactured and sold by Heyden Chemical Corporation (hereinafter “Heyden”), a Delaware corporation. On December 1, 1953, Hey-den’s Antibiotics Division, including its Thoratrast assets and business, was acquired by Cyanamid, and Heyden ceased its involvement with the drug. In the purchase agreement, Heyden obligated itself to defend and indemnify Cyanamid from and against any and all claims arising out of the operation of the Antibiotics Division prior to the closing date. In 1957, Thoro-trast was allegedly administered to plaintiffs’ decedent at Mercy Hospital in New Orleans. Also in 1957, Heyden changed its name to Heyden Newport Chemical Corporation. On June 28,1963, TRI (then known as HDN Corporation) was incorporated pursuant to the laws of Delaware. On October 4, 1963, TRI purchased the then existing assets of Heyden Newport, which assets did not include Thorotrast.

After being named as a defendant in plaintiffs’ action, TRI filed an exception of lack of personal jurisdiction on the grounds that it had never participated in the manufacture, sale, or distribution of Thorotrast, and that, as a nonresident corporation, it could therefore not be subjected to the jurisdiction of a Louisiana court in a claim involving Thorotrast. The trial court sustained the exception, and dismissed plaintiffs’ claim against TRI. This judgment was not appealed and is now final.

In the meantime, codefendant Cyanamid filed a cross claim against TRI for indemnity based upon Heyden’s agreement to defend and indemnify Cyanamid contained in the 1953 sale of Heyden’s Antibiotics Division to Cyanamid. TRI asserted an exception to personal jurisdiction as to the cross claim, which exception was maintained by the trial court. Cyanamid now appeals that judgment.

There are two possible bases for the assertion of personal jurisdiction over TRI in the instant case. The first is the Louisiana Longarm Statute, R.S. 13:3201 et seq., which sets forth in detail the conditions under which a Louisiana court may assert personal jurisdiction over a nonresident. The second possible basis for jurisdiction is the appellant’s claim that TRI has voluntarily submitted to the jurisdiction of the court. See La.Code Civ.Pro. art. 6. In our view, neither of these provisions would justify the exercise of jurisdiction over TRI in this case.

R.S. 13:3201 prior to the 1987 amendments thereto, provided, in pertinent part, that a Louisiana court may exercise jurisdiction over a nonresident “as to a cause of action arising from any one of the following activities performed by the nonresident:

(1) Transacting any business in this state.
(2) Contracting to supply services or things in this state.
(3) Causing injury or damages by an offense or quasi-offense committed through an act or omission in this state.
(4) Causing injury or damage in this state by an offense or quasi-offense committed through an act or omission outside of this state, if he regularly does or solicits business, or engages in any other persistent course of conduct or derives revenue from goods used or consumed or services rendered in this state.
[1113]*1113(5) ...
(6) ...
(7) ...
(8) Manufacturing of a product or component thereof which caused damage or injury in this state, if at the time of placing the product into the stream of commerce, the manufacturer could have foreseen, realized, expected, or anticipated that the product may eventually be found in this state by reason of its nature and the manufacturer’s marketing practices.”

It is undisputed that TRI did not perform any of the enumerated activities in this state. TRI itself has never engaged in the manufacture, sale or distribution of Thoro-trast in any state.

The law is clear that R.S. 18:3201 authorizes jurisdiction over a nonresident only as to a cause of action arising from the nonresident’s activity or conduct in Louisiana. See: R.S. 13:3202 (Repealed-1987); Ingram Contractors, Inc. v. Rowley, 360 So.2d 593, 594 (La.App. 4th Cir. 1978), writ denied, 363 So.2d 72 (La.1978). In this case, the principal demand does not arise from TRI’s activity in this state, but rather from TRI’s purchase of Heyden, which allegedly manufactured the Thoro-trast that was administered to plaintiffs’ decedent in Louisiana. Moreover, this appeal is not concerned with the principal demand, but with the cross claim asserted by Cyanamid against TRI. The cross claim seeks indemnification from TRI based upon TRI’s alleged assumption, when it purchased Heyden’s assets, of an agreement Heyden had made ten years before to indemnify Cyanamid. As both TRI and Cyanamid are foreign corporations which do not do business in Louisiana, it is clear that this indemnity provision could be enforced in several other forums. Furthermore, considering the extremely attenuated nature of the connection, if indeed there is any, between this cross claim and Louisiana, we see no reason for a Louisiana court to exercise jurisdiction.

The crux of Cyanamid’s argument on this point is that TRI, as the successor of Heyden, is subject to jurisdiction under 13:3201 because of the alleged activities of Heyden in manufacturing Thorotrast, which ultimately wound up in Louisiana. However, appellant has not been able to cite any holding from our state courts in which R.S. 13:3201 has been used to assert jurisidiction over a nonresident based not upon the activities of the nonresident itself, but upon the activities of its predecessor corporation. We will not go beyond the clear words of the statute, which refers to “activities performed by the nonresident.” R.S. 13:3201 (Emphasis added.)

Moreover, even if we were inclined to interpet the statute in the manner suggested by appellant, we are not certain that TRI can be characterized as the “successor” of Heyden. Appellant cites several cases from other jurisdictions, as well as one federal case from the Middle District of Louisiana, in which jurisdiction has been asserted over successor corporations based upon the actions of their predecessors. See, e.g.: Duris v. Erato Shipping, Inc., 684 F.2d 352 (6th Cir.1982), cert. granted, Pallas Shipping Agency Ltd. v. Duris, 459 U.S. 1014, 103 S.Ct. 371, 74 L.Ed.2d 506, and judgment affirmed, by Pallas Shipping Agency Ltd. v. Duris, 461 U.S. 529, 103 S.Ct. 1991, 76 L.Ed.2d 120; Fehl v. C.W.C. Corp., 433 F.Supp. 939 (D.Del. 1977); United States v. Bliss, 108 F.R.D. 127 (E.D.Mi.1985);

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Simmers v. American Cyanamid Corp.
576 A.2d 376 (Supreme Court of Pennsylvania, 1990)

Cite This Page — Counsel Stack

Bluebook (online)
518 So. 2d 1111, 1987 La. App. LEXIS 10898, 1987 WL 2803, Counsel Stack Legal Research, https://law.counselstack.com/opinion/sullivan-v-fellows-testagar-co-lactapp-1987.